Profund Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.33M | Buy |
17,687
+1,987
| +13% | +$264K | 0.09% | 166 |
|
|
2025
Q4 | $2.23M | Buy |
15,700
+1,631
| +12% | +$236K | 0.07% | 198 |
|
|
2025
Q3 | $1.98M | Sell |
14,069
-3,657
| -21% | -$496K | 0.06% | 194 |
|
|
2025
Q2 | $2.23M | Sell |
17,726
-4,327
| -20% | -$496K | 0.08% | 167 |
|
|
2025
Q1 | $2.44M | Buy |
22,053
+330
| +2% | +$41.8K | 0.11% | 149 |
|
|
2024
Q4 | $2.97M | Sell |
21,723
-7,385
| -25% | -$913K | 0.11% | 131 |
|
|
2024
Q3 | $3.35M | Buy |
29,108
+4,791
| +20% | +$657K | 0.13% | 122 |
|
|
2024
Q2 | $3.35M | Buy |
24,317
+10,405
| +75% | +$1.43M | 0.12% | 120 |
|
|
2024
Q1 | $1.92M | Sell |
13,912
-1,359
| -9% | -$186K | 0.07% | 176 |
|
|
2023
Q4 | $2.01M | Sell |
15,271
-736
| -5% | -$84.7K | 0.09% | 172 |
|
|
2023
Q3 | $1.8M | Sell |
16,007
-2,847
| -15% | -$300K | 0.1% | 160 |
|
|
2023
Q2 | $1.78M | Buy |
18,854
+2,636
| +16% | +$258K | 0.1% | 167 |
|
|
2023
Q1 | $1.64M | Buy |
16,218
+2,330
| +17% | +$242K | 0.1% | 170 |
|
|
2022
Q4 | $1.66M | Buy |
13,888
+305
| +2% | +$35.7K | 0.11% | 175 |
|
|
2022
Q3 | $1.44M | Sell |
13,583
-512
| -4% | -$52K | 0.1% | 176 |
|
|
2022
Q2 | $1.37M | Sell |
14,095
-1,483
| -10% | -$137K | 0.09% | 194 |
|
|
2022
Q1 | $1.46M | Sell |
15,578
-1,696
| -10% | -$144K | 0.06% | 244 |
|
|
2021
Q4 | $1.47M | Sell |
17,274
-2,636
| -13% | -$242K | 0.05% | 245 |
|
|
2021
Q3 | $1.91M | Sell |
19,910
-1,233
| -6% | -$116K | 0.06% | 231 |
|
|
2021
Q2 | $2.06M | Sell |
21,143
-437
| -2% | -$41.9K | 0.07% | 223 |
|
|
2021
Q1 | $2.1M | Buy |
21,580
+2,540
| +13% | +$266K | 0.08% | 197 |
|
|
2020
Q4 | $1.82M | Buy |
19,040
+1,708
| +10% | +$165K | 0.08% | 211 |
|
|
2020
Q3 | $1.67M | Sell |
17,332
-3,247
| -16% | -$376K | 0.09% | 201 |
|
|
2020
Q2 | $2.51M | Buy |
20,579
+3,274
| +19% | +$362K | 0.14% | 129 |
|
|
2020
Q1 | $1.5M | Sell |
17,305
-6,312
| -27% | -$618K | 0.11% | 153 |
|
|
2019
Q4 | $2.54M | Buy |
23,617
+2,541
| +12% | +$266K | 0.11% | 155 |
|
|
2019
Q3 | $1.9M | Sell |
21,076
-1,413
| -6% | -$132K | 0.1% | 196 |
|
|
2019
Q2 | $1.9M | Sell |
22,489
-2,816
| -11% | -$231K | 0.09% | 211 |
|
|
2019
Q1 | $2.23M | Buy |
25,305
+387
| +2% | +$32.3K | 0.11% | 175 |
|
|
2018
Q4 | $1.78M | Sell |
24,918
-6,011
| -19% | -$576K | 0.11% | 177 |
|
|
2018
Q3 | $3.8M | Buy |
30,929
+3,018
| +11% | +$342K | 0.14% | 117 |
|
|
2018
Q2 | $2.74M | Sell |
27,911
-1,399
| -5% | -$125K | 0.11% | 148 |
|
|
2018
Q1 | $2.43M | Sell |
29,310
-3,104
| -10% | -$262K | 0.1% | 168 |
|
|
2017
Q4 | $2.52M | Sell |
32,414
-4,077
| -11% | -$278K | 0.1% | 173 |
|
|
2017
Q3 | $2.24M | Buy |
36,491
+2,889
| +9% | +$152K | 0.09% | 194 |
|
|
2017
Q2 | $1.55M | Sell |
33,602
-1,919
| -5% | -$93.1K | 0.07% | 255 |
|
|
2017
Q1 | $1.54M | Sell |
35,521
-2,832
| -7% | -$121K | 0.07% | 266 |
|
|
2016
Q4 | $1.48M | Sell |
38,353
-6,069
| -14% | -$275K | 0.07% | 253 |
|
|
2016
Q3 | $2.25M | Buy |
44,422
+1,377
| +3% | +$68.6K | 0.11% | 161 |
|
|
2016
Q2 | $1.96M | Sell |
43,045
-3,972
| -8% | -$183K | 0.1% | 168 |
|
|
2016
Q1 | $1.86M | Sell |
47,017
-10,859
| -19% | -$431K | 0.1% | 165 |
|
|
2015
Q4 | $3.27M | Sell |
57,876
-225
| -0.4% | -$11.4K | 0.16% | 92 |
|
|
2015
Q3 | $2.31M | Buy |
+58,101
| New | +$2.81M | 0.13% | 109 |
|
Other funds holding NBIX
VPM
VCM
Profund Advisors's NBIX Position: Q1 2026 in Review
Profund Advisors increased its Neurocrine Biosciences (NBIX) stake by 13% in Q1 2026, buying an estimated $264K and bringing the position to 17,687 shares worth $2.33M. The position accounts for 0.09% of the portfolio, ranked #166.
Profund Advisors first reported a position in NBIX in Q3 2015 and has held it in 43 quarters since. The position peaked at $3.8M in Q3 2018. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Profund Advisors held 17,687 shares of Neurocrine Biosciences worth $2.33M as of Q1 2026.
- Profund Advisors bought 1,987 Neurocrine Biosciences shares in Q1 2026, an estimated $264K.
- Neurocrine Biosciences made up 0.09% of Profund Advisors's portfolio in Q1 2026, its #166 holding.
- Profund Advisors first reported a position in Neurocrine Biosciences in Q3 2015 and has held it in 43 quarters since.
- Profund Advisors's Neurocrine Biosciences position peaked at $3.8M in Q3 2018.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.